Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AIM ImmunoTech ( (AIM) ) has shared an announcement.
In January 2026, AIM ImmunoTech furnished a corporate presentation outlining its ongoing and planned activities to evaluate Ampligen as a treatment for a range of viral diseases, cancers and immune-deficiency disorders, while emphasizing that the material is being provided for informational purposes rather than as a formal, liability-bearing filing. The company underscored that Ampligen remains in early-stage development with significant additional animal and human testing required, and cautioned investors about substantial risks, including the possibility of unsuccessful or inconclusive clinical trials, regulatory and funding uncertainties, and operational challenges associated with conducting studies and protecting intellectual property in foreign markets.
The most recent analyst rating on (AIM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is heavily impacted by its poor financial performance and valuation. The company’s significant financial challenges, including persistent losses and a weak balance sheet, are the most critical factors. Technical analysis also points to a bearish trend, further weighing down the score. The absence of positive earnings call data or corporate events leaves little room for optimism.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech is a biotechnology company focused on developing immuno-modulatory therapies, notably its experimental drug Ampligen, aimed at treating multiple types of viral diseases, cancers and immune-deficiency disorders in various global markets.
Average Trading Volume: 106,053
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.79M
See more insights into AIM stock on TipRanks’ Stock Analysis page.